Digoxin toxicity with therapeutic serum digoxin concentrations [PDF]
Toxicology ReportsIntroduction: Digoxin is a cardiac glycoside used for rate control in atrial fibrillation and heart failure. Despite its efficacy, digoxin has a narrow therapeutic window and can cause severe side effects, including life-threatening arrhythmias ...
J. Graafsma +5 more
doaj +3 more sources
Floral phantosmia and bradycardia: A unique case of digoxin toxicity in an elderly patient [PDF]
Turkish Journal of Emergency MedicineThis case report presents a rare clinical manifestation of digoxin toxicity in a 73-year-old female with acute kidney injury, bradycardia, and unique sensory disturbances, including phantosmia (floral scent hallucinations) and photopsia (seeing sparkles ...
Marsida Kasa +4 more
doaj +2 more sources
Management of digoxin toxicity. [PDF]
Aust Prescr, 2016 Digoxin toxicity can emerge during long-term therapy as well as after an overdose. It can occur even when the serum digoxin concentration is within the therapeutic range. Toxicity causes anorexia, nausea, vomiting and neurological symptoms. It can also trigger fatal arrhythmias.
Pincus M.
europepmc +4 more sources
Characterizing Utilization and Outcomes of Digoxin Immune Fab for Digoxin Toxicity [PDF]
Drugs - Real World OutcomesBackground Digoxin is a widely prescribed drug for congestive heart failure and atrial fibrillation. Digoxin has a narrow therapeutic index and toxicity can develop quite easily.
Sophia Sheikh +10 more
doaj +2 more sources
Stone heart syndrome: A curious case of digoxin toxicity and calcium infusion [PDF]
Clinical Case ReportsKey Clinical Message Stone heart syndrome has a complex interaction with digoxin toxicity, where, theoretically, the administration of intravenous calcium can worsen a patient's condition.
Guleid Hussein +12 more
doaj +2 more sources
Reconsidering Digoxin in Atrial Fibrillation: From Historical Controversy to Physiologically Guided and Personalized Rate Control [PDF]
BiomedicinesBackground: The role of digoxin in atrial fibrillation, particularly in patients with heart failure, has long been debated. Observational studies reporting higher mortality have fueled skepticism, yet growing evidence suggests that these findings largely
Silvia Ana Luca +7 more
doaj +2 more sources
Colored floaters as a manifestation of digoxin toxicity [PDF]
American Journal of Ophthalmology Case Reports, 2018 Purpose: Since its report in one patient more than 70 years ago, digitalis-induced colored muscae volitantes have not surfaced again in the literature. We report here a case of digoxin induced colored floaters. Observations: An 89-year-old man on 0.25 mg
Lynn Shi, Linus D. Sun, Jeffrey G. Odel
doaj +2 more sources
Inappropriate use of digoxin in patients presenting with digoxin toxicity. [PDF]
J Geriatr Cardiol, 2015 PubMed ID ...
Tatlisu MA +5 more
europepmc +4 more sources
Physiologically Based Pharmacokinetic Modeling of Digoxin in Adult and Pediatric Patients with Heart Failure [PDF]
PharmaceuticsBackground/Objectives: Digoxin is a cardiotonic agent with a narrow therapeutic window and a high risk of toxicity. The current clinical use is based on an empirically FDA-recommended regimen which has wide dosing ranges, introducing the risk of ...
Yicui Zhang, Yao Liu, Hua He, Kun Hao
doaj +2 more sources
Predicting Pharmacokinetics of Drugs in Patients with Heart Failure and Optimizing Their Dosing Strategies Using a Physiologically Based Pharmacokinetic Model [PDF]
PharmaceuticsBackground: Heart failure (HF), as the end stage of various cardiac diseases, alters blood flow to key organs responsible for drug clearance. This can lead to unpredictable and often suboptimal drug exposure, creating a critical need for quantitative ...
Weiye Gu, Qingxuan Shao, Ling Jiang
doaj +2 more sources